Predictive factors of persistent thrombocytopenia after 177Lu-DOTATATE in patients with neuroendocrine tumors

#4054

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an effective and well tolerated treatment for advanced Neuroendocrine Tumors (NET). However, some Persistent Thrombocytopenia (PT) are described and may compromise further therapies and outcome.

Aim(s): To identify predictive factors of PT defined as a platelet count <100 x 109/L, two months after the end of PRRT.

Materials and methods: We reported a retrospective analysis of 47 patients (25 female, 22 male, median age 68y) with metastatic NET (ileal: 89.4%) who received PRRT with a median cumulative administrated activity of 29.1 GBq 177Lu-DOTATATE (12.6-30.1). The Initial Decline of Platelets count (IDPC) was defined as the relative change (%) in platelets count between the baseline and the nadir value before the second PPRT cycle. Bone metastatic volume was quantitatively measured on baseline Somatostatin Receptor Imaging and converted into an Osteo-Medullary Invasion Score (OMIS) by allocating a percentage of active marrow. Spleen length was measured on baseline CT.

Conference:

Presenting Author:

Authors: Oziel-Taieb S, Ferrara R, Charrier N, Maniry J, Reichert T,

Keywords: Neuroendocrine Tumor, PRRT, LuDOTATATE, Thrombocytopenia, Bone metastases, spleen,